Photrexa Viscous

Drug Overview

In the clinical specialty of Ophthalmology, maintaining the structural integrity of the eye is vital for clear vision. For patients suffering from progressive thinning and bulging of the cornea, standard topical treatments are often insufficient. Photrexa Viscous represents a transformative medical intervention for these individuals. It is a specialized ophthalmic solution falling under the Photosensitizer drug class, designed specifically for use in a procedure known as corneal collagen cross-linking (CXL).

Photrexa Viscous is a high-purity, riboflavin-based formulation. Unlike standard drops used for infection or inflammation, this medication serves as a primary catalyst in a Targeted Therapy designed to physically strengthen the cornea’s biological “scaffolding.” By halting the progression of degenerative corneal diseases, it offers a critical alternative to more invasive procedures like a Corneal Transplant.

• Generic Name: Riboflavin 5-phosphate
• Active Ingredient: Riboflavin 5-phosphate (0.146%)
• US Brand Names: Photrexa Viscous
• Route of Administration: Topical Drops (Surgical application to the corneal stroma)
• FDA Approval Status: FDA-approved for use with the KXL System for corneal cross-linking.

What Is It and How Does It Work? (Mechanism of Action)

Photrexa Viscous is a viscous riboflavin solution that functions through a photochemical reaction. Its role is twofold: it acts as a Photosensitizer to induce structural changes and as a protective shield for the deeper structures of the eye.

At the molecular and physiological level, the mechanism of action is a process called corneal collagen cross-linking:

1. Saturation: The viscous solution is applied to the cornea (following the removal of the outer epithelial layer). Due to its viscosity, the riboflavin remains in contact with the corneal stroma, ensuring deep and uniform saturation of the collagen fibers.
2. Photoactivation: Once the cornea is saturated, it is exposed to controlled Ultraviolet-A (UVA) light. The riboflavin molecules in Photrexa Viscous absorb this light energy, reaching an “excited” state.
3. Singlet Oxygen Generation: The excited riboflavin reacts with oxygen molecules within the corneal tissue to produce reactive oxygen species, specifically singlet oxygen.
4. Cross-Link Formation: This singlet oxygen induces the formation of new covalent chemical bonds—or “cross-links”—between adjacent collagen fibrils. This process effectively stiffens and reinforces the corneal matrix, increasing its mechanical stability and resistance to further bulging.
5. UVA Absorption: Simultaneously, the riboflavin acts as a filter, absorbing approximately 90% of the UVA light. This prevents the potentially harmful radiation from reaching and damaging the delicate Retinal Pigment Epithelium (RPE) and the crystalline lens.

FDA-Approved Clinical Indications

Photrexa Viscous is meticulously indicated for patients facing progressive structural failure of the anterior eye.

• Primary Indication: Treatment of progressive keratoconus, a condition where the cornea thins and gradually bulges outward into a cone shape.
• Other Approved & Off-Label Uses: Treatment of corneal ectasia following refractive surgery (such as LASIK). While primarily used for these conditions, ongoing research explores its potential in treating severe infectious keratitis (PACK-CXL), though this remains an off-label application.

Primary Ophthalmology Indications for visual preservation:

• Stabilizing Ocular Geometry: By strengthening the collagen bonds, the drug prevents the cornea from continuing to steepen. This is essential for preventing the severe irregular astigmatism that leads to vision loss.
• Preserving Visual Acuity: While the goal is stabilization rather than a “cure,” halting disease progression ensures that the patient’s Best Corrected Visual Acuity (BCVA) does not continue to decline over time.
• Avoiding Invasive Surgery: This Targeted Therapy is used to stabilize the cornea early in the disease process, significantly reducing the long-term clinical necessity for a full-thickness corneal transplant.

Dosage and Administration Protocols

Photrexa Viscous is administered exclusively by an ophthalmologist in a controlled surgical environment. It is not intended for self-administration by the patient.

Indication	Standard Dose	Frequency
Progressive Keratoconus	1 drop every 2 minutes for 30 minutes	Single-session surgical procedure
Post-Refractive Ectasia	1 drop every 2 minutes for 30 minutes	Single-session surgical procedure

Administration Specifics:

• Epithelial Removal: The procedure typically begins with the removal of the corneal epithelium (“Epi-Off” technique) to allow the viscous solution to penetrate the stroma.
• Saturation Phase: Drops are applied consistently for 30 minutes. The clinician checks for the presence of riboflavin in the anterior chamber (using a slit-lamp) to confirm full penetration.
• UVA Irradiation Phase: After saturation, UVA light is applied for an additional 30 minutes, during which Photrexa (non-viscous) or Photrexa Viscous continues to be applied every 2 minutes.
• Post-Operative Care: A bandage contact lens is typically placed on the eye immediately following the procedure to facilitate epithelial healing.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Current clinical study data (updated for 2020-2026) continues to validate riboflavin cross-linking as the gold standard for keratoconus stabilization. In randomized, multi-center trials, patients treated with Photrexa Viscous demonstrated a significant reduction in corneal steepness compared to untreated control groups.

Precise numerical data from longitudinal studies indicates that treated eyes show a mean reduction in maximum keratometry (Kmax) of approximately 1.5 to 2.0 diopters at the 12-month mark, whereas untreated eyes typically show an increase of 1.0 diopter or more. Regarding visual outcomes, while the procedure is not a refractive “fix,” studies show that the Best Corrected Visual Acuity (BCVA) remains stable or improves by 1 to 2 letters on the ETDRS chart in over 80% of treated patients. Furthermore, research data confirms that the mechanical stiffness of the cornea increases by over 300% following treatment. Unlike a VEGF Inhibitor that manages fluid, or Targeted Therapy for Intraocular Pressure (IOP), the efficacy of Photrexa is measured by the halt of structural deformation, which is efficacious in preventing the “drop-off” in vision associated with end-stage corneal disease.

Safety Profile and Side Effects

Black Box Warning: There is NO “Black Box Warning” for Photrexa Viscous. However, the procedure involves the temporary removal of the corneal’s protective barrier, requiring strict post-operative vigilance.

Common Side Effects (>10%):

• Corneal haze (temporary cloudiness of the cornea).
• Eye pain or significant discomfort during the first 24-72 hours.
• Punctate keratitis (small surface irritations).
• Blurred vision during the epithelial healing phase.

Serious Adverse Events:

• Infectious Keratitis: A serious bacterial or viral infection of the cornea due to the temporary lack of an epithelial barrier.
• Corneal Melting: Extremely rare, but may occur if healing is severely delayed or in patients with underlying autoimmune disease.
• Endophthalmitis: Highly rare, as this is an extraocular procedure.
• Delayed Epithelial Healing: The surface layer may take longer than expected to regrow, increasing the risk of scarring.

Management Strategies:

Sterile administration is mandatory throughout the surgery. Post-operatively, patients must use prophylactic Antibiotic and steroid drops. Management of pain includes the use of oral analgesics and a bandage contact lens. Patients must monitor for “floaters” or sudden, sharp pain, which could indicate a post-surgical complication.

Research Areas

Direct Clinical Connections:

Recent research is investigating the interaction between cross-linking and goblet cell density. Because the procedure affects the ocular surface, scientists are studying how to preserve the tear film during the healing phase to avoid chronic dry eye symptoms.

Generalization:

Active clinical trials (2020-2026) are focusing on Novel Delivery Systems, such as “Epi-On” cross-linking. This involves using specialized formulations to penetrate the cornea without removing the epithelium, potentially reducing pain and infection risk. There is also research into Preservative-Free post-operative regimens to support patients with sensitive ocular surfaces.

Severe Disease & Surgical Integration:

Photrexa is being researched for its efficacy in stabilizing the cornea before or after specific refractive surgeries to prevent blindness from secondary ectasia. It is also being integrated as an adjunct to “Intacs” (corneal ring segments) to maximize structural reinforcement in end-stage cases.

Disclaimer: These studies regarding ocular surface effects of corneal cross-linking, novel “Epi-On” delivery systems, preservative-free regimens, and potential adjunct surgical applications of riboflavin-based therapies are currently in preclinical or early clinical investigation phases and are not yet applicable to practical or professional clinical scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

A rigorous baseline is essential to ensure the cornea is thick enough (typically >400 microns) for safe treatment.

• Baseline Diagnostics: Record Baseline Visual Acuity, Tonometry (IOP measurement), and a slit-lamp exam.
• Ocular Imaging: Mandatory Corneal Topography and tomographic maps to measure corneal steepness and thickness.
• Specialized Testing: Pachymetry to ensure the thinnest point of the cornea meets the safety threshold.
• Screening: Review history of ocular surgeries, Herpes Simplex Keratitis, and any autoimmune conditions that affect wound healing.

Monitoring and Precautions

• Vigilance: Monitor for signs of infection daily until the epithelial layer has completely closed.
• Lifestyle: Strict UV protection (sunglasses) is required for several weeks post-surgery, as the eye is more sensitive to light. Eyelid hygiene (lid scrubs) is encouraged before surgery to minimize bacterial load.
• Nutrition: While not directly curative, maintaining overall eye health through dietary supplements (such as Vitamin C) may support collagen health.

Do’s and Don’ts

• DO follow the antibiotic drop schedule exactly as prescribed to prevent blinding infections.
• DO report any sudden increase in pain or redness immediately.
• DON’T rub your eyes for at least one month following the procedure.
• DON’T swim or use a hot tub until the ophthalmologist confirms the epithelial barrier has healed.

Legal Disclaimer

This guide is provided for educational and informational purposes only and does not constitute medical advice or a recommendation for a specific surgical procedure. Standard clinical protocols and FDA approvals are subject to change. Always seek the advice of an ophthalmologist or other qualified healthcare professional regarding any medical condition. Never disregard professional medical advice because of something you have read in this guide. Standard medical information is not a substitute for an individualized clinical assessment.